The only non-reimbursed Evrysdi struggle in the market
By Jung, Sae-Im | translator Kim, Jung-Ju
23.05.31 05:50:40
가나다라
0
SMA market in Q1 recorded KRW 20 billion in sales... Evrysdi posts sales of KRW 300 million
Ranks No.2 in global sales, the leading product in the US and Japan
Its non-reimbursement remains a barrier in Korea for over 2 years...will be deliberated at DREC in June
▲(From the left) Spinraza, Evrysdi, Zolgensma
It has been 1 year and 6 months since the only oral spinal muscular atrophy (SMA) treatment, ‘Evrysdi (risdiplam),’ has been released in the Korean market. However, the company is having trouble posting sales in Korea. This is in stark contrast to how the same product exceeded the sales of 'Zolgensma' and is comparable to the sales of 'Spinraza.’ The fact that the reimbursement application was not even discussed for nearly 2 years and its reimbursement was blocked acted as a barrier in Korea. However, the Health Insurance Review and Assessment Service plan to review Evrysdi at its Drug Reimbursement Evaluation Committee (DREC) soon.
According to the market research institution IQVIA on the 3
Jung, Sae-Im (same@dailypharm.com)
If you want to see the full article, please JOIN US (click)